The in vitro candidacidal activity of a yeast killer toxin-like monoclonal antibody (mAbK10) and a synthetic killer mimotope (KM) has been evaluated against 71 oral Candida isolates characterized by different patterns of susceptibility to 6 conventional antifungal drugs. Candida strains were isolated from diabetic patients as well as from a population of control subjects who did not have diabetes mellitus. The results show that mAbK10 and KM exerted a strong candidacidal activity against all of the yeast isolates tested. The activity proved to be related to the interaction with a • glucan component of the yeast cell wall. This peculiar mechanism of action makes reasonable the effectiveness of mAbK10 and KM also against isolates proved to be resistant to conventional antifungal drugs. MAbK10 and KM may be considered a new molecular model to generate antifungal drugs that overcome the currently recognized mechanisms of resistance in clinical isolates of Candida species.
Full conference title:
The 15 th Congress of the International Society for Human and Animal Mycology
- ISHAM 15th (2003)